BIOMERICA INC (BMRA) Fundamental Analysis & Valuation
NASDAQ:BMRA • US09061H4065
Current stock price
2.18 USD
0 (0%)
Last:
This BMRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BMRA Profitability Analysis
1.1 Basic Checks
- BMRA had negative earnings in the past year.
- BMRA had a negative operating cash flow in the past year.
- BMRA had negative earnings in each of the past 5 years.
- BMRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -85.57%, BMRA is not doing good in the industry: 78.61% of the companies in the same industry are doing better.
- The Return On Equity of BMRA (-125.84%) is worse than 68.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.57% | ||
| ROE | -125.84% | ||
| ROIC | N/A |
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BMRA has a worse Gross Margin (4.32%) than 81.28% of its industry peers.
- In the last couple of years the Gross Margin of BMRA has declined.
- The Profit Margin and Operating Margin are not available for BMRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 4.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
2. BMRA Health Analysis
2.1 Basic Checks
- BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- BMRA has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BMRA has been increased compared to 5 years ago.
- BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- BMRA has an Altman-Z score of -15.53. This is a bad value and indicates that BMRA is not financially healthy and even has some risk of bankruptcy.
- BMRA has a worse Altman-Z score (-15.53) than 86.63% of its industry peers.
- BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.53 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
- A Current Ratio of 2.64 indicates that BMRA has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.64, BMRA is in line with its industry, outperforming 50.27% of the companies in the same industry.
- BMRA has a Quick Ratio of 1.59. This is a normal value and indicates that BMRA is financially healthy and should not expect problems in meeting its short term obligations.
- BMRA has a Quick ratio (1.59) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.64 | ||
| Quick Ratio | 1.59 |
3. BMRA Growth Analysis
3.1 Past
- BMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.60%, which is quite impressive.
- BMRA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.81%.
- BMRA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.51% yearly.
EPS 1Y (TTM)28.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-11.53%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BMRA Valuation Analysis
4.1 Price/Earnings Ratio
- BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BMRA Dividend Analysis
5.1 Amount
- No dividends for BMRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BMRA Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:BMRA (4/28/2026, 8:15:37 PM)
2.18
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength10.56
Industry Growth62.11
Earnings (Last)04-13 2026-04-13/amc
Earnings (Next)N/A N/A
Inst Owners2.96%
Inst Owner Change0%
Ins Owners14.06%
Ins Owner Change0%
Market Cap6.74M
Revenue(TTM)4.33M
Net Income(TTM)-4.17M
Analysts85.71
Price TargetN/A
Short Float %2.33%
Short Ratio2.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.03 | ||
| P/tB | 2.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS1.4
BVpS1.07
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.57% | ||
| ROE | -125.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 4.32% | ||
| FCFM | N/A |
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
F-Score3
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 22.89% | ||
| Cap/Sales | 0.44% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.64 | ||
| Quick Ratio | 1.59 | ||
| Altman-Z | -15.53 |
F-Score3
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)94.83%
Cap/Depr(5y)109.76%
Cap/Sales(3y)1.44%
Cap/Sales(5y)1.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-11.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.93%
OCF growth 3YN/A
OCF growth 5YN/A
BIOMERICA INC / BMRA Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for BIOMERICA INC?
ChartMill assigns a fundamental rating of 1 / 10 to BMRA.
What is the valuation status for BMRA stock?
ChartMill assigns a valuation rating of 0 / 10 to BIOMERICA INC (BMRA). This can be considered as Overvalued.
What is the profitability of BMRA stock?
BIOMERICA INC (BMRA) has a profitability rating of 0 / 10.